FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2165655216> ?p ?o ?g. }

• W2165655216 abstract "For years, the pharmaceutical industry has relied heavily on crystalline active pharmaceutical ingredients (APIs) that can be approved by the Federal Drug Administration (FDA) as neutral compounds, salts, or solvates of said neutral compounds and salts. Yet, the solid crystalline form can have unexpected and unfavorable effects on properties such as solubility, bioavailability, efficacy, etc., due to different polymorphic forms of the API. A drug can be present in multiple forms and interconvert between forms during isolation, manufacturing, storage, and transport of the end product. These unwelcome problems could be alleviated or even eliminated by the formation of a liquid drug, which possesses no crystal structure. Unfortunately, research in this area has been limited to solubilization of solid drugs into various drug delivery vehicles such as emulsions, suspensions, and liposomes. However, it is possible for a drug to crystallize from these vehicles during the manufacturing, storage, and transportation. Thus, a new method to liquefy pharmaceuticals, thereby reducing problems associated with the solid-state, is needed. A potential solution is the use of ionic liquids (IL), defined as salts that melt below 100 °C. Since ILs are salts it is possible to combine a pharmaceutical ion with any desired counter ion, thereby, providing a level of tunablity that is not possible with current techniques. This IL modular strategy was the basis for the research discussed here, in which APIs with known problems were combined with GRAS (generally regarded as safe) compounds or FDA-approved APIs, which resulted in ILs displaying dual biological functionality. This strategy was successful in producing a wide range of ILs, all containing at least one pharmaceutically active ion. The physical property set for these synthesized ILs was varied, as it is difficult to predict how two ionic organic compounds will interact. However, common trends regarding melting point depression, thermal stability, and solubility were determined. The most exciting results were exhibited during the biological testing, as several of the synthesized ILs demonstrated improved biological activity over the precursor ions. Additionally, the drug mechanism, at a cellular level, was found to be modified when contained within an IL. This indicates that ILs behavior differently in the body than simple halide containing salts. Overall, the obtained results signify that ILs can serve as pharmaceuticals, in which these liquid salts eliminate problems associated with the solid-state and displayed to synergistic physical and biological properties." @default.
• W2165655216 created "2016-06-24" @default.
• W2165655216 creator A5051176796 @default.
• W2165655216 date "2010-01-01" @default.
• W2165655216 modified "2023-09-23" @default.
• W2165655216 title "FUNCTIONAL IONIC LIQUIDS FOR USE IN PHARMACEUTICAL APPLICATIONS" @default.
• W2165655216 cites W1500500354 @default.
• W2165655216 cites W1526629922 @default.
• W2165655216 cites W1578864054 @default.
• W2165655216 cites W2087787638 @default.
• W2165655216 cites W2603162409 @default.
• W2165655216 cites W30792185 @default.
• W2165655216 cites W3164394167 @default.
• W2165655216 cites W48337641 @default.
• W2165655216 cites W571726088 @default.
• W2165655216 cites W651534235 @default.
• W2165655216 hasPublicationYear "2010" @default.
• W2165655216 type Work @default.
• W2165655216 sameAs 2165655216 @default.
• W2165655216 citedByCount "1" @default.
• W2165655216 countsByYear W21656552162014 @default.
• W2165655216 crossrefType "dissertation" @default.
• W2165655216 hasAuthorship W2165655216A5051176796 @default.
• W2165655216 hasConcept C106186310 @default.
• W2165655216 hasConcept C127413603 @default.
• W2165655216 hasConcept C154881586 @default.
• W2165655216 hasConcept C155574463 @default.
• W2165655216 hasConcept C161790260 @default.
• W2165655216 hasConcept C171250308 @default.
• W2165655216 hasConcept C178790620 @default.
• W2165655216 hasConcept C181389837 @default.
• W2165655216 hasConcept C183696295 @default.
• W2165655216 hasConcept C185592680 @default.
• W2165655216 hasConcept C192562407 @default.
• W2165655216 hasConcept C21880701 @default.
• W2165655216 hasConcept C21951064 @default.
• W2165655216 hasConcept C2778938233 @default.
• W2165655216 hasConcept C2779535233 @default.
• W2165655216 hasConcept C2779652045 @default.
• W2165655216 hasConcept C2779820397 @default.
• W2165655216 hasConcept C2780035454 @default.
• W2165655216 hasConcept C43617362 @default.
• W2165655216 hasConcept C45904493 @default.
• W2165655216 hasConcept C71924100 @default.
• W2165655216 hasConcept C98274493 @default.
• W2165655216 hasConceptScore W2165655216C106186310 @default.
• W2165655216 hasConceptScore W2165655216C127413603 @default.
• W2165655216 hasConceptScore W2165655216C154881586 @default.
• W2165655216 hasConceptScore W2165655216C155574463 @default.
• W2165655216 hasConceptScore W2165655216C161790260 @default.
• W2165655216 hasConceptScore W2165655216C171250308 @default.
• W2165655216 hasConceptScore W2165655216C178790620 @default.
• W2165655216 hasConceptScore W2165655216C181389837 @default.
• W2165655216 hasConceptScore W2165655216C183696295 @default.
• W2165655216 hasConceptScore W2165655216C185592680 @default.
• W2165655216 hasConceptScore W2165655216C192562407 @default.
• W2165655216 hasConceptScore W2165655216C21880701 @default.
• W2165655216 hasConceptScore W2165655216C21951064 @default.
• W2165655216 hasConceptScore W2165655216C2778938233 @default.
• W2165655216 hasConceptScore W2165655216C2779535233 @default.
• W2165655216 hasConceptScore W2165655216C2779652045 @default.
• W2165655216 hasConceptScore W2165655216C2779820397 @default.
• W2165655216 hasConceptScore W2165655216C2780035454 @default.
• W2165655216 hasConceptScore W2165655216C43617362 @default.
• W2165655216 hasConceptScore W2165655216C45904493 @default.
• W2165655216 hasConceptScore W2165655216C71924100 @default.
• W2165655216 hasConceptScore W2165655216C98274493 @default.
• W2165655216 hasLocation W21656552161 @default.
• W2165655216 hasOpenAccess W2165655216 @default.
• W2165655216 hasPrimaryLocation W21656552161 @default.
• W2165655216 hasRelatedWork W143602621 @default.
• W2165655216 hasRelatedWork W145528718 @default.
• W2165655216 hasRelatedWork W1493178899 @default.
• W2165655216 hasRelatedWork W1542159547 @default.
• W2165655216 hasRelatedWork W1624822012 @default.
• W2165655216 hasRelatedWork W166416874 @default.
• W2165655216 hasRelatedWork W1978272050 @default.
• W2165655216 hasRelatedWork W1979220369 @default.
• W2165655216 hasRelatedWork W2046179634 @default.
• W2165655216 hasRelatedWork W2048284581 @default.
• W2165655216 hasRelatedWork W2063781602 @default.
• W2165655216 hasRelatedWork W2088828170 @default.
• W2165655216 hasRelatedWork W2105552142 @default.
• W2165655216 hasRelatedWork W2185858535 @default.
• W2165655216 hasRelatedWork W2188404643 @default.
• W2165655216 hasRelatedWork W2226790321 @default.
• W2165655216 hasRelatedWork W2895851747 @default.
• W2165655216 hasRelatedWork W3125490798 @default.
• W2165655216 hasRelatedWork W3128667138 @default.
• W2165655216 hasRelatedWork W850224875 @default.
• W2165655216 isParatext "false" @default.
• W2165655216 isRetracted "false" @default.
• W2165655216 magId "2165655216" @default.
• W2165655216 workType "dissertation" @default.